Foley & Lardner LLP Associate Sunny Levine is quoted in the Kaiser Health News article, “Behavioral Telehealth Loses Momentum Without a Regulatory Boost,” discussing the U.S. Department of Health and Human Services’ Substance Abuse and Mental Health Services Administration (SAMHSA) recent proposal to codify telehealth regulation on opioid treatment programs.
While this proposal only affects part of the sector and leaves unaddressed the process for individual providers to register to prescribe buprenorphine, Levine said the new rules “get us at least a little bit closer to where we need to go.”
This article also ran in CBS News.
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”